JP2005519916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519916A5 JP2005519916A5 JP2003563467A JP2003563467A JP2005519916A5 JP 2005519916 A5 JP2005519916 A5 JP 2005519916A5 JP 2003563467 A JP2003563467 A JP 2003563467A JP 2003563467 A JP2003563467 A JP 2003563467A JP 2005519916 A5 JP2005519916 A5 JP 2005519916A5
- Authority
- JP
- Japan
- Prior art keywords
- limited
- dideoxy
- construction
- alkenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 phosphate ester Chemical class 0.000 claims description 84
- 125000003342 alkenyl group Chemical group 0.000 claims description 64
- 125000000217 alkyl group Chemical group 0.000 claims description 62
- 125000000304 alkynyl group Chemical group 0.000 claims description 62
- 125000003118 aryl group Chemical group 0.000 claims description 52
- 150000001875 compounds Chemical class 0.000 claims description 49
- 229910052731 fluorine Inorganic materials 0.000 claims description 49
- 229910052794 bromium Inorganic materials 0.000 claims description 45
- 229910052801 chlorine Inorganic materials 0.000 claims description 45
- 229910052740 iodine Inorganic materials 0.000 claims description 41
- 125000001188 haloalkyl group Chemical group 0.000 claims description 38
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 26
- 125000004001 thioalkyl group Chemical group 0.000 claims description 26
- 229910019142 PO4 Inorganic materials 0.000 claims description 24
- 239000010452 phosphate Substances 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 15
- 150000003014 phosphoric acid esters Chemical class 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 13
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 5
- 238000010276 construction Methods 0.000 claims 27
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 13
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 13
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 10
- ZZOWHGNRJBACEC-OBNKUBODSA-N 6-amino-6-(4-bromobenzoyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one Chemical compound C1=C(F)C(N)(C(=O)C=2C=CC(Br)=CC=2)NC(=O)N1[C@H]1CC[C@@H](CO)O1 ZZOWHGNRJBACEC-OBNKUBODSA-N 0.000 claims 3
- QFZSFOGFWZZUNY-OBNKUBODSA-N 6-amino-6-(4-chlorobenzoyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one Chemical compound ClC1=CC=C(C(=O)C2(NC(N([C@H]3CC[C@@H](CO)O3)C=C2F)=O)N)C=C1 QFZSFOGFWZZUNY-OBNKUBODSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- XPZKEBBLAZUJAS-OBNKUBODSA-N 6-amino-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-6-(4-iodobenzoyl)-1H-pyrimidin-2-one Chemical compound IC1=CC=C(C(=O)C2(NC(N([C@H]3CC[C@@H](CO)O3)C=C2F)=O)N)C=C1 XPZKEBBLAZUJAS-OBNKUBODSA-N 0.000 claims 2
- DJVMNMGZLLNCOX-OBNKUBODSA-N 6-amino-5-fluoro-6-(4-fluorobenzoyl)-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one Chemical compound C1=C(F)C(N)(C(=O)C=2C=CC(F)=CC=2)NC(=O)N1[C@H]1CC[C@@H](CO)O1 DJVMNMGZLLNCOX-OBNKUBODSA-N 0.000 claims 2
- GYKMBBKSGZJFDI-POXCNRTASA-N 6-amino-6-(4-ethylbenzoyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one Chemical compound C1=CC(CC)=CC=C1C(=O)C1(N)C(F)=CN([C@@H]2O[C@H](CO)CC2)C(=O)N1 GYKMBBKSGZJFDI-POXCNRTASA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- OEPQUYSQHIUHDR-HCWSKCQFSA-N 4-amino-1-[(2s,3r,4s,5r)-2-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@]1(F)[C@H](O)[C@H](O)[C@@H](CO)O1 OEPQUYSQHIUHDR-HCWSKCQFSA-N 0.000 claims 1
- STRZQWQNZQMHQR-UAKXSSHOSA-N 5-fluorocytidine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 STRZQWQNZQMHQR-UAKXSSHOSA-N 0.000 claims 1
- WLVNAHXIMSQHMW-OCDMVOQQSA-N 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-ethylbenzoyl)-5-fluoro-1H-pyrimidin-2-one Chemical compound C(C)C1=CC=C(C(=O)C2(NC(N([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)C=C2F)=O)N)C=C1 WLVNAHXIMSQHMW-OCDMVOQQSA-N 0.000 claims 1
- LJTXIDHLSJRCRI-JYCRYNECSA-N 6-amino-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-6-(4-methoxybenzoyl)-1H-pyrimidin-2-one Chemical compound C1=CC(OC)=CC=C1C(=O)C1(N)C(F)=CN([C@H]2C=C[C@@H](CO)O2)C(=O)N1 LJTXIDHLSJRCRI-JYCRYNECSA-N 0.000 claims 1
- ORAFXVZDHPCYMY-QQDBQQHDSA-N 6-amino-6-(1-benzothiophene-2-carbonyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one Chemical compound C1=C(F)C(N)(C(=O)C=2SC3=CC=CC=C3C=2)NC(=O)N1[C@H]1CC[C@@H](CO)O1 ORAFXVZDHPCYMY-QQDBQQHDSA-N 0.000 claims 1
- BSSDTTPDXHUFRY-OBNKUBODSA-N 6-amino-6-(3-bromobenzoyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one Chemical compound C1=C(F)C(N)(C(=O)C=2C=C(Br)C=CC=2)NC(=O)N1[C@H]1CC[C@@H](CO)O1 BSSDTTPDXHUFRY-OBNKUBODSA-N 0.000 claims 1
- BDVFEQPECMQQEK-OBNKUBODSA-N 6-amino-6-(4-bromobenzoyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-1H-pyrimidin-2-one Chemical compound C1=C(F)C(N)(C(=O)C=2C=CC(Br)=CC=2)NC(=O)N1[C@@H]1O[C@H](CO)C=C1 BDVFEQPECMQQEK-OBNKUBODSA-N 0.000 claims 1
- VCLLXLWPTDLADT-OBNKUBODSA-N 6-amino-6-(4-chlorobenzoyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-1H-pyrimidin-2-one Chemical compound C1=C(F)C(N)(C(=O)C=2C=CC(Cl)=CC=2)NC(=O)N1[C@@H]1O[C@H](CO)C=C1 VCLLXLWPTDLADT-OBNKUBODSA-N 0.000 claims 1
- NOIZCHKDVXBABB-DBMQZSJKSA-N 6-amino-6-(4-tert-butylbenzoyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)C1(N)C(F)=CN([C@@H]2O[C@H](CO)CC2)C(=O)N1 NOIZCHKDVXBABB-DBMQZSJKSA-N 0.000 claims 1
- YLCCKDTVZYPNME-OBNKUBODSA-N 6-amino-6-(cyclohexanecarbonyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-1H-pyrimidin-2-one Chemical compound C1=C(F)C(N)(C(=O)C2CCCCC2)NC(=O)N1[C@@H]1O[C@H](CO)C=C1 YLCCKDTVZYPNME-OBNKUBODSA-N 0.000 claims 1
- AMHSVLOKQVVFRS-OBNKUBODSA-N 6-amino-6-(cyclohexanecarbonyl)-5-fluoro-3-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-2-one Chemical compound C1(CCCCC1)C(=O)C1(NC(N([C@H]2CC[C@@H](CO)O2)C=C1F)=O)N AMHSVLOKQVVFRS-OBNKUBODSA-N 0.000 claims 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004401 m-toluyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C(*)=O 0.000 claims 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 description 29
- 150000002367 halogens Chemical class 0.000 description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 239000000651 prodrug Substances 0.000 description 22
- 229940002612 prodrug Drugs 0.000 description 22
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 239000001177 diphosphate Substances 0.000 description 11
- 235000011180 diphosphates Nutrition 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 150000003904 phospholipids Chemical class 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 239000001226 triphosphate Substances 0.000 description 11
- 235000011178 triphosphate Nutrition 0.000 description 11
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 10
- 0 *C[C@@](*1)*C(*)(*)[C@]1N(C=C(*)C(NC(*)=O)=N1)C1=O Chemical compound *C[C@@](*1)*C(*)(*)[C@]1N(C=C(*)C(NC(*)=O)=N1)C1=O 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34155501P | 2001-12-14 | 2001-12-14 | |
| PCT/US2002/040081 WO2003063771A2 (en) | 2001-12-14 | 2002-12-13 | N4-acylcytosine nucleosides for treatment of viral iinfections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519916A JP2005519916A (ja) | 2005-07-07 |
| JP2005519916A5 true JP2005519916A5 (enExample) | 2010-03-18 |
Family
ID=23338072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003563467A Pending JP2005519916A (ja) | 2001-12-14 | 2002-12-13 | ウィルス感染治療用ｎ４−アシルシトシンヌクレオシド類 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US7105527B2 (enExample) |
| EP (1) | EP1569652A4 (enExample) |
| JP (1) | JP2005519916A (enExample) |
| KR (1) | KR100978904B1 (enExample) |
| CN (1) | CN100560073C (enExample) |
| AU (2) | AU2002365234B2 (enExample) |
| BR (1) | BR0214944A (enExample) |
| CA (1) | CA2470255C (enExample) |
| MX (1) | MXPA04005779A (enExample) |
| WO (2) | WO2003063771A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6790228B2 (en) * | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
| KR100974917B1 (ko) | 2000-04-13 | 2010-08-09 | 파마셋 인코포레이티드 | 간염 바이러스 감염 치료를 위한 3'- 또는2'-하이드록시메틸 치환된 뉴클레오시드 유도체 |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| AU2001272923A1 (en) | 2000-05-26 | 2001-12-11 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
| CN100560073C (zh) * | 2001-12-14 | 2009-11-18 | 法玛塞特公司 | 用于治疗病毒感染的n4-酰基胞嘧啶核苷 |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| KR20050035194A (ko) * | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘 |
| WO2004013300A2 (en) | 2002-08-01 | 2004-02-12 | Pharmasset Inc. | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections |
| CN1849142A (zh) * | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′－支链核苷和黄病毒突变 |
| KR20050109918A (ko) | 2002-12-12 | 2005-11-22 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드의 제조 방법 |
| CA2425031A1 (en) * | 2003-04-01 | 2004-10-01 | Smithkline Beecham Corporation | Pharmaceutical compositions |
| KR100883703B1 (ko) * | 2003-05-30 | 2009-02-12 | 파마셋 인코포레이티드 | 변형 불소화 뉴클레오시드 유사체 |
| WO2005097618A2 (en) * | 2004-04-01 | 2005-10-20 | Achillion Pharmaceuticals, Inc. | Low dose therapy for treating viral infections |
| CN101023094B (zh) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| EP3109244B1 (en) | 2004-09-14 | 2019-03-06 | Gilead Pharmasset LLC | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| EP1802315A2 (en) * | 2004-10-19 | 2007-07-04 | Achillion Pharmaceuticals, Inc. | Combination therapy for treating viral infections |
| US7968703B2 (en) * | 2005-03-07 | 2011-06-28 | Shire Canada Inc. | Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof |
| WO2007075876A2 (en) * | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| MX2011006891A (es) | 2008-12-23 | 2011-10-06 | Pharmasset Inc | Fosforamidatos de nucleosidos. |
| US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| CN102753563A (zh) | 2008-12-23 | 2012-10-24 | 吉利德制药有限责任公司 | 核苷类似物 |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| EA026341B9 (ru) | 2010-03-31 | 2021-12-27 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Кристаллическая форма нуклеозидфосфорамидата |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN103242400B (zh) * | 2012-02-08 | 2016-06-08 | 河南师范大学 | 具有抗hiv活性的5-取代嘧啶核苷-噻唑啉酮杂化体及其制备方法 |
| UA118256C2 (uk) | 2013-01-31 | 2018-12-26 | Гіліад Фармассет Елелсі | Комбінований склад двох противірусних сполук |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| AU2017324939B2 (en) | 2016-09-07 | 2021-10-14 | Atea Pharmaceuticals, Inc. | 2'-substituted-N6-substituted purine nucleotides for RNA virus treatment |
| US10519186B2 (en) | 2017-02-01 | 2019-12-31 | Atea Pharmaceuticals, Inc. | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus |
| KR20200140865A (ko) | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | 간경변증을 갖는 hcv 감염 환자의 치료 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| CN117500494A (zh) | 2021-06-17 | 2024-02-02 | 阿堤亚制药公司 | 有利的抗hcv联合疗法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US13660A (en) * | 1855-10-09 | Improvements | ||
| US3309359A (en) * | 1965-10-22 | 1967-03-14 | Hoffmann La Roche | N-mono-acyl-5-fluorocytosine derivatives and process |
| NL8202626A (nl) | 1982-06-29 | 1984-01-16 | Stichting Rega V Z W | Derivaten van 9-(2-hydroxyethoxymethyl)guanine. |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
| ZA886890B (en) * | 1987-10-09 | 1989-05-30 | Hoffmann La Roche | Novel dideoxycytidine derivatives |
| US6350753B1 (en) * | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
| NL8901258A (nl) | 1989-05-19 | 1990-12-17 | Stichting Rega V Z W | 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties. |
| DD293498A5 (de) | 1989-07-20 | 1991-09-05 | Zi Fuer Molekularbiologie Der Adw,De | Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier |
| JPH05310777A (ja) | 1992-05-14 | 1993-11-22 | Yoshitomi Pharmaceut Ind Ltd | ２’−デオキシ−２’−メチリデンシチジン化合物 |
| TW254946B (enExample) * | 1992-12-18 | 1995-08-21 | Hoffmann La Roche | |
| TW374087B (en) | 1993-05-25 | 1999-11-11 | Univ Yale | L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents |
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US5703058A (en) | 1995-01-27 | 1997-12-30 | Emory University | Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent |
| GB9525606D0 (en) * | 1995-12-14 | 1996-02-14 | Iaf Biochem Int | Method and compositions for the synthesis of dioxolane nucleosides with - configuration |
| WO1998017281A1 (en) * | 1996-10-24 | 1998-04-30 | Vion Pharmaceuticals, Inc. | MONOPHOSPHATE PRODRUGS OF β-L-FD4C AND β-L-FddC AS POTENT ANTIVIRAL AGENTS |
| CA2311581A1 (en) * | 1997-11-25 | 1999-06-03 | Protarga, Inc. | Nucleoside analog compositions and uses thereof |
| US6348587B1 (en) | 1998-02-25 | 2002-02-19 | Emory University | 2′-Fluoronucleosides |
| CA2425359A1 (en) * | 2000-10-13 | 2002-04-18 | Shire Biochem Inc. | Dioxolane analogs for improved inter-cellular delivery |
| EP1411954B1 (en) * | 2000-10-18 | 2010-12-15 | Pharmasset, Inc. | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
| CN100560073C (zh) * | 2001-12-14 | 2009-11-18 | 法玛塞特公司 | 用于治疗病毒感染的n4-酰基胞嘧啶核苷 |
-
2002
- 2002-12-13 CN CNB028278402A patent/CN100560073C/zh not_active Expired - Fee Related
- 2002-12-13 CA CA2470255A patent/CA2470255C/en not_active Expired - Fee Related
- 2002-12-13 BR BR0214944-3A patent/BR0214944A/pt not_active Application Discontinuation
- 2002-12-13 WO PCT/US2002/040081 patent/WO2003063771A2/en not_active Ceased
- 2002-12-13 AU AU2002365234A patent/AU2002365234B2/en not_active Ceased
- 2002-12-13 KR KR1020047009263A patent/KR100978904B1/ko not_active Expired - Fee Related
- 2002-12-13 EP EP02804833A patent/EP1569652A4/en not_active Withdrawn
- 2002-12-13 JP JP2003563467A patent/JP2005519916A/ja active Pending
- 2002-12-13 MX MXPA04005779A patent/MXPA04005779A/es active IP Right Grant
- 2002-12-13 US US10/318,511 patent/US7105527B2/en not_active Expired - Fee Related
- 2002-12-16 AU AU2002364730A patent/AU2002364730A1/en not_active Abandoned
- 2002-12-16 US US10/320,350 patent/US6908924B2/en not_active Ceased
- 2002-12-16 WO PCT/US2002/040090 patent/WO2003051306A2/en not_active Ceased
-
2006
- 2006-07-31 US US11/461,338 patent/US20070078080A1/en not_active Abandoned
-
2007
- 2007-06-21 US US11/821,076 patent/USRE42015E1/en not_active Expired - Fee Related
-
2008
- 2008-01-04 US US11/969,427 patent/US8114997B2/en not_active Expired - Fee Related
-
2012
- 2012-02-13 US US13/371,654 patent/US20120202766A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519916A5 (enExample) | ||
| JP7126947B2 (ja) | 抗ウイルス剤によるｂ型肝炎ウイルスの排除 | |
| CA2470255A1 (en) | N4-acylcytosine nucleosides for treatment of viral infections | |
| JP2013056886A5 (enExample) | ||
| CN101142198B (zh) | 用于治疗疾病的异*唑坎布雷它斯丁衍生物 | |
| KR20220026538A (ko) | 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체 | |
| CN103561576A (zh) | 脂质合成的杂环调节剂 | |
| JP2020521740A5 (enExample) | ||
| ZA200400925B (en) | Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | |
| CN103664897A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| JP2005523922A5 (enExample) | ||
| JP2017531019A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2004533401A5 (enExample) | ||
| JP2006509749A5 (enExample) | ||
| CN101484449A (zh) | 整合酶抑制剂-3 | |
| EP2346329A1 (en) | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds | |
| RU2004100302A (ru) | Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью, способ их получения, их применение в качестве лекарственного или диагностического средства, а также содержащие их фармацевтические композиции | |
| JP2023547599A (ja) | リン脂質化合物及びその使用 | |
| JP2018530582A5 (enExample) | ||
| JP2004525183A5 (enExample) | ||
| JP2006516643A5 (enExample) | ||
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral | |
| US11219633B2 (en) | Nucleobase analogue derivatives and their applications | |
| JP2002533470A5 (enExample) |